ABVC BIOPHARMA, INC.
For the period ended Dec 31, 2025. Filed Mar 3, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 3, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on March 3, 2026
| ABVC BioPharma, Inc. | |
| By: | /s/ Uttam Patil |
| Uttam Patil | |
| Chief Executive Officer (Principal Executive Officer) | |
| By: | /s/ Uttam Patil |
| Uttam Patil | |
| Interim Chief Financial Officer (Principal Financial Officer) |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:
| Signature | Title | Date |
|---|---|---|
| /s/ Uttam Patil | Chief Executive Officer (Principal Executive Officer) | March 3, 2026 |
| Uttam Patil | ||
| /s/ Uttam Patil | Interim Chief Financial Officer (Principal Financial Officer) | March 3, 2026 |
| Uttam Patil | ||
| /s/ Eugene Jiang | Chairman of the Board of Directors | March 3, 2026 |
| Eugene Jiang | ||
| /s/ Yen-Hsin Chou | Director | March 3, 2026 |
| Yen-Hsin Chou | ||
| /s/ Hsin-Hui Miao | Director | March 3, 2026 |
| Hsin-Hui Miao | ||
| /s/ Tsang-Ming Jiang | Director | March 3, 2026 |
| Tsang-Ming Jiang | ||
| /s/ Shuling Jiang | Director | March 3, 2026 |
| Shuling Jiang | ||
| /s/ Norimi Sakamoto | Director | March 3, 2026 |
| Norimi Sakamoto | ||
| /s/ Tsung-Shann Jiang | Director | March 3, 2026 |
| Tsung-Shann Jiang | ||
| /s/ Chang-Jen Jiang | Director | March 3, 2026 |
| Chang-Jen Jiang | ||
| /s/ Yoshinobu Odaira | Director | March 3, 2026 |
| Yoshinobu Odaira | ||
| /s/ Che-Wei Hsu | Director | March 3, 2026 |
| Che-Wei Hsu | ||
| /s/ Yu-Min (Francis) Chung | Director | March 3, 2026 |
| Yu-Min (Francis) Chung | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.